Tuesday, May 29, 2007

Talima Therapeutics Raises $19M

Santa Clara-based Talima Therapeutics has raised $19M in a Series B round, the firm said Tuesday morning. The round was led by US Venture Partners and Latterell Venture Partners. Prior investors De Novo Ventures and Palo Alto Healthcare also participated in the funding round. The funding will go towards Phase II clincal trials for the firm's site-specific, drug delivery technology. The firm's micro-implant technology is focused on providing local applications of systemic drugs to dermatology patients, such as those with psoriasis. More information »